Appendix 4C - June 2019 Quarter
Filed with ASX ·
6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Telix Receives $9.3m R&D Tax Refund
- Investor Presentation
- Telix announces completion of $40.0 million Placement
- Telix Reports Positive Phase III Meeting with the FDA
- Telix and Monrol Manufacturing and Distribution Agreement
Later from Telix Pharmaceuticals
- Sales Note to Accompany June 2019 Quarter Appendix 4C
- Telix and Merck Group Combination Therapy Collaboration
- Telix and GenesisCare Commence Prostate Cancer Study
- Telix Pharmaceuticals announces results of successful SPP
- First Australian Patient Dosed in ZIRCON Phase III Trial
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals